好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates
Multiple Sclerosis
P4 - Poster Session 4 (11:45 AM-12:45 PM)
6-005
To assess the effectiveness of fumarates (FUM) in Black, Hispanic, Asian, and White people with multiple sclerosis (pwMS).
Racial/ethnic minority patient populations are generally underrepresented in clinical trials. Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are disease-modifying therapies for relapsing MS. Data describing FUM effectiveness in racial/ethnic pwMS are limited. 
This retrospective analysis of the Komodo Health Claims Database included patients 18-64 years old with ≥1 claim for MS diagnosis and a claim for DMF or DRF between 01-Jan-2017 to 31-May-2022. Index date was the first FUM claim date. Patients were followed from index to first occurrence of end of study, end of insurance eligibility, gap >45 days, or DMT switch.

This analysis included 1241 Black, 777 Hispanic, 132 Asian, and 4650 White pwMS treated with FUM. Baseline mean (SD) MS severity scores were: Black, 7.1 (4.2); Hispanic, 6.4 (4.0); Asian, 6.0 (3.3); and White, 6.4 (4.1). Baseline (1 year pre-index) annualized relapse rate (ARR) (95% CI) was 0.338 (0.297-0.385) in Black patients, compared with 0.311 (0.258-0.376), 0.295 (0.212-0.412), and 0.299 (0.273-0.326) in Hispanic, Asian, and White patients, respectively. Mean FUM exposure post-index ranged from 449-559 days. Post-index, ARR (95% CI) reduced to 0.252 (0.212-0.300) in Black patients, compared with 0.185 (0.138-0.248), 0.163 (0.104-0.256), and 0.214 (0.182-0.251) in Hispanic, Asian, and White patients, respectively. Estimated proportions relapse-free (95% CI) at 24 months were: Black, 77.0% (73.7%-80.3%); Hispanic, 75.4% (71.0%-80.0%), Asian, 81.7% (73.0%-90.3%); and White, 80.5% (70.0%-82.1%). Absolute lymphocyte count reductions (95% CI) after 12 months on FUM were 10.3% (3.8%-16.3%), 20.1% (14.8%-25.1%), 14.4% (0.6%-26.3%) and 20.4% (18.0%-22.7%) in Black, Hispanic, Asian, and White patients, respectively.
Similar FUM efficacy was observed in all racial/ethnic subgroups in this analysis of 2150 racial/ethnic minority pwMS, consistent with prior studies. 
Authors/Disclosures
Sophia Woodson
PRESENTER 		No disclosure on file
Edward J. Gettings, DO (Temple University) Dr. Gettings has nothing to disclose.
Chu-Yueh Guo, MD (UCSF Medical Center) Dr. Guo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics.
Sylvia Klineova, MD (Icahn School of Medicine At Mount Sinai) Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Klineova has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Klineova has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Klineova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
Jong-Mi Lee, NP (Jong-Mi Lee) Ms. Lee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Ms. Lee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol meyers Squibb . Ms. Lee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Ms. Lee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon.
Rebecca Romero, MD, FAAN (UTHSCSA) Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics . Dr. Romero has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon.
Aljoeson Walker, MD No disclosure on file
Kinyee Fong (Biogen) Dr. Fong has received personal compensation for serving as an employee of Biogen. Dr. Fong has stock in Biogen.
Jason Mendoza (Biogen) No disclosure on file
Nicholas Belviso, PhD, PharmD Dr. Belviso has received personal compensation for serving as an employee of Biogen.
Boyang Bian Boyang Bian has received personal compensation for serving as an employee of Biogen. Boyang Bian has stock in Biogen.
James B. Lewin, PharmD Dr. Lewin has received personal compensation for serving as an employee of Biogen. Dr. Lewin has stock in Biogen.
Sai L. Shankar, PhD, FAAN (Biogen) Dr. Shankar has received personal compensation for serving as an employee of Biogen. Dr. Shankar has stock in Biogen.